<p>Castle Biosciences, Inc. (NASDAQ:CSTL - 获取免费报告) 首席财务官 Frank Stokes 于 3 月 3 日星期二出售了 7,000 股 Castle Biosciences 股票。股票的平均售价为 27.44 美元，总交易额为 192,080.00 美元。出售后，首席财务官直接持有公司 52,483 股股票，价值 1,440,133.52 美元。这代表其持股减少了 11.77%。该交易已在向 SEC 提交的文件中披露，文件可通过此链接获取。</p>
<p>获取 <strong>Castle Biosciences</strong> 的提醒：</p>
<h2>Castle Biosciences 股票下跌 0.9%</h2>
<p>NASDAQ CSTL 周四下跌 0.26 美元，达到 27.91 美元。该股票交易了 419,929 股，而其平均交易量为 445,124 股。该公司的市值为 8.2976 亿美元，市盈率为 -32.84，贝塔值为 1.09。该公司的债务与股本比率为 0.02，速动比率为 5.11，流动比率为 5.26。Castle Biosciences, Inc. 的 12 个月低点为 14.59 美元，12 个月高点为 44.28 美元。该公司的 50 日移动平均价格为 36.41 美元，200 日移动平均价格为 31.38 美元。</p>
<p>Castle Biosciences (NASDAQ:CSTL - 获取免费报告) 最近于 2 月 26 日星期四发布了季度财报。公司报告该季度每股收益为 -0.08 美元，超出分析师一致预期的 -0.23 美元，超出幅度为 0.15 美元。该季度公司收入为 8,188 万美元，而分析师预期为 8,119 万美元。Castle Biosciences 的净利润率为 -7.02%，股本回报率为 -0.89%。作为一个整体，研究分析师预测 Castle Biosciences, Inc. 本财年将发布 0.44 美元的每股收益。</p>
<h2>Castle Biosciences 的机构交易</h2>
<p>几家对冲基金和其他机构投资者最近对该公司的持股进行了调整。凯通国际资产管理有限公司在第四季度将其在 Castle Biosciences 的股份增加了 188.3%。凯通国际资产管理有限公司现在拥有 2,099 股公司股票，价值 82,000 美元，此前在上个季度购买了 1,371 股。景顺投资有限公司在第四季度将其在 Castle Biosciences 的股份增加了 142.6%。景顺投资有限公司现在拥有 135,461 股公司股票，价值 5,269,000 美元，此前在上个季度购买了 79,621 股。麦肯齐金融公司在第四季度将其在 Castle Biosciences 的持股增加了 54.2%。麦肯齐金融公司现在拥有 37,317 股公司股票，价值 1,464,000 美元，此前在上个季度收购了 13,113 股。Empowered Funds LLC 在第四季度将其在 Castle Biosciences 的持股增加了 24.2%。Empowered Funds LLC 现在拥有 121,920 股公司股票，价值 4,743,000 美元，此前在上个季度收购了 23,740 股。最后，XTX Topco Ltd 在第四季度购买了 Castle Biosciences 的新股份，价值约 861,000 美元。对冲基金和其他机构投资者持有公司 92.60% 的股票。</p>
<h2>华尔街分析师预测增长</h2>
<p>一些股票分析师最近对该股票发表了评论。BTIG Research 将 Castle Biosciences 的目标价格从 38.00 美元上调至 50.00 美元，并在 12 月 12 日的研究报告中给予该股票 &#34;买入&#34; 评级。罗伯特·W·贝尔德将 Castle Biosciences 的目标价格从 41.00 美元上调至 44.00 美元，并在 2 月 27 日的报告中给予公司 &#34;跑赢大盘&#34; 评级。摩根士丹利在周一的研究报告中将 Castle Biosciences 的评级上调至 &#34;买入&#34;。Canaccord Genuity Group 将 Castle Biosciences 的目标价格从 37.00 美元上调至 50.00 美元，并在 12 月 22 日的研究报告中给予公司 &#34;买入&#34; 评级。最后，Weiss Ratings 在 12 月 29 日的研究报告中重申了对 Castle Biosciences 股票的 &#34;卖出 (d)&#34; 评级。八位研究分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股票的共识评级为 &#34;适度买入&#34;，平均目标价格为 47.57 美元。</p>
<p><strong>阅读我们关于 CSTL 的最新研究报告</strong></p>
<h2>关于 Castle Biosciences</h2>
<p>(获取免费报告)</p>
<p>Castle Biosciences, Inc 是一家分子诊断公司，专注于为皮肤病患者开发和商业化预后和诊断测试。该公司的专有基因组检测组合旨在改善风险评估并指导皮肤癌及其他皮肤相关疾病患者的临床决策。通过将基因组数据与先进的统计算法相结合，Castle Biosciences 力求提供可操作的见解，帮助医生量身定制治疗方案和监测策略。</p>
<p>该公司的旗舰测试 DecisionDx-Melanoma 评估皮肤黑色素瘤患者的转移概率，支持更个性化的监测和治疗方法。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过 Castle Biosciences</li>
<li>华尔街害怕的黄金图表……</li>
<li>美国的 1776 再次发生</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>用这 4 个简单步骤 &#34;防止美联储&#34; 你的银行账户</li>
<li>解锁：埃隆·马斯克的下一个大 IPO</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1NUTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1NUTA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Castle Biosciences 吗？</h2>
<p>在你考虑 Castle Biosciences 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Castle Biosciences 并不在名单上。</p>
<p>虽然 Castle Biosciences 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

IBBQ

基因改革 ETF - ARK

纳斯达克生物科技指数 ETF - iShares Nasdaq

<p>Castle Biosciences 首席财务官 Frank Stokes 出售了 7,000 股公司股票，平均价格为 27.44 美元，总计 192,080 美元。出售后，他持有 52,483 股，反映出其持股减少了 11.77%。该交易已向美国证券交易委员会（SEC）披露。Castle Biosciences 的股票最近下跌 0.9%，报 27.91 美元，市值为 8.2976 亿美元。分析师对该公司的共识评级为 “适度买入”，平均目标价格为 47.57 美元</p>

<p>Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) CFO Frank Stokes sold 7,000 shares of Castle Biosciences stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $27.44, for a total transaction of $192,080.00. Following the sale, the chief financial officer directly owned 52,483 shares of the company's stock, valued at $1,440,133.52. This represents a 11.77% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.</p>
<div class="lb-trans"><p>Castle Biosciences, Inc. (NASDAQ:CSTL - 获取免费报告) 首席财务官 Frank Stokes 于 3 月 3 日星期二出售了 7,000 股 Castle Biosciences 股票。股票的平均售价为 27.44 美元，总交易额为 192,080.00 美元。出售后，首席财务官直接持有公司 52,483 股股票，价值 1,440,133.52 美元。这代表其持股减少了 11.77%。该交易已在向 SEC 提交的文件中披露，文件可通过此链接获取。</p>
</div><p>Get <strong>Castle Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Castle Biosciences</strong> 的提醒：</p>
</div><h2>Castle Biosciences Stock Down 0.9%</h2>
<div class="lb-trans"><h2>Castle Biosciences 股票下跌 0.9%</h2>
</div><p>NASDAQ CSTL traded down $0.26 on Thursday, reaching $27.91. 419,929 shares of the stock traded hands, compared to its average volume of 445,124. The company has a market cap of $829.76 million, a price-to-earnings ratio of -32.84 and a beta of 1.09. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.11 and a current ratio of 5.26. Castle Biosciences, Inc. has a 12 month low of $14.59 and a 12 month high of $44.28. The company has a fifty day moving average price of $36.41 and a 200-day moving average price of $31.38.</p>
<div class="lb-trans"><p>NASDAQ CSTL 周四下跌 0.26 美元，达到 27.91 美元。该股票交易了 419,929 股，而其平均交易量为 445,124 股。该公司的市值为 8.2976 亿美元，市盈率为 -32.84，贝塔值为 1.09。该公司的债务与股本比率为 0.02，速动比率为 5.11，流动比率为 5.26。Castle Biosciences, Inc. 的 12 个月低点为 14.59 美元，12 个月高点为 44.28 美元。该公司的 50 日移动平均价格为 36.41 美元，200 日移动平均价格为 31.38 美元。</p>
</div><p>Castle Biosciences (NASDAQ:CSTL - Get Free Report) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.23) by $0.15. The company had revenue of $81.88 million during the quarter, compared to analyst estimates of $81.19 million. Castle Biosciences had a negative net margin of 7.02% and a negative return on equity of 0.89%. As a group, research analysts forecast that Castle Biosciences, Inc. will post 0.44 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Castle Biosciences (NASDAQ:CSTL - 获取免费报告) 最近于 2 月 26 日星期四发布了季度财报。公司报告该季度每股收益为 -0.08 美元，超出分析师一致预期的 -0.23 美元，超出幅度为 0.15 美元。该季度公司收入为 8,188 万美元，而分析师预期为 8,119 万美元。Castle Biosciences 的净利润率为 -7.02%，股本回报率为 -0.89%。作为一个整体，研究分析师预测 Castle Biosciences, Inc. 本财年将发布 0.44 美元的每股收益。</p>
</div><h2>Institutional Trading of Castle Biosciences</h2>
<div class="lb-trans"><h2>Castle Biosciences 的机构交易</h2>
</div><p>Several hedge funds and other institutional investors have recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd grew its stake in Castle Biosciences by 188.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,099 shares of the company's stock worth $82,000 after buying an additional 1,371 shares during the last quarter. Invesco Ltd. raised its stake in Castle Biosciences by 142.6% in the fourth quarter. Invesco Ltd. now owns 135,461 shares of the company's stock valued at $5,269,000 after buying an additional 79,621 shares during the last quarter. Mackenzie Financial Corp boosted its holdings in Castle Biosciences by 54.2% in the fourth quarter. Mackenzie Financial Corp now owns 37,317 shares of the company's stock worth $1,464,000 after acquiring an additional 13,113 shares in the last quarter. Empowered Funds LLC boosted its holdings in Castle Biosciences by 24.2% in the fourth quarter. Empowered Funds LLC now owns 121,920 shares of the company's stock worth $4,743,000 after acquiring an additional 23,740 shares in the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of Castle Biosciences during the fourth quarter worth about $861,000. Hedge funds and other institutional investors own 92.60% of the company's stock.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近对该公司的持股进行了调整。凯通国际资产管理有限公司在第四季度将其在 Castle Biosciences 的股份增加了 188.3%。凯通国际资产管理有限公司现在拥有 2,099 股公司股票，价值 82,000 美元，此前在上个季度购买了 1,371 股。景顺投资有限公司在第四季度将其在 Castle Biosciences 的股份增加了 142.6%。景顺投资有限公司现在拥有 135,461 股公司股票，价值 5,269,000 美元，此前在上个季度购买了 79,621 股。麦肯齐金融公司在第四季度将其在 Castle Biosciences 的持股增加了 54.2%。麦肯齐金融公司现在拥有 37,317 股公司股票，价值 1,464,000 美元，此前在上个季度收购了 13,113 股。Empowered Funds LLC 在第四季度将其在 Castle Biosciences 的持股增加了 24.2%。Empowered Funds LLC 现在拥有 121,920 股公司股票，价值 4,743,000 美元，此前在上个季度收购了 23,740 股。最后，XTX Topco Ltd 在第四季度购买了 Castle Biosciences 的新股份，价值约 861,000 美元。对冲基金和其他机构投资者持有公司 92.60% 的股票。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of equities analysts recently commented on the stock. BTIG Research boosted their price objective on shares of Castle Biosciences from $38.00 to $50.00 and gave the stock a &#34;buy&#34; rating in a research note on Friday, December 12th. Robert W. Baird lifted their price target on Castle Biosciences from $41.00 to $44.00 and gave the company an &#34;outperform&#34; rating in a report on Friday, February 27th. Morgan Stanley upgraded Castle Biosciences to a &#34;buy&#34; rating in a research note on Monday. Canaccord Genuity Group raised their price objective on Castle Biosciences from $37.00 to $50.00 and gave the company a &#34;buy&#34; rating in a research report on Monday, December 22nd. Finally, Weiss Ratings reiterated a &#34;sell (d)&#34; rating on shares of Castle Biosciences in a research note on Monday, December 29th. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $47.57.</p>
<div class="lb-trans"><p>一些股票分析师最近对该股票发表了评论。BTIG Research 将 Castle Biosciences 的目标价格从 38.00 美元上调至 50.00 美元，并在 12 月 12 日的研究报告中给予该股票 &#34;买入&#34; 评级。罗伯特·W·贝尔德将 Castle Biosciences 的目标价格从 41.00 美元上调至 44.00 美元，并在 2 月 27 日的报告中给予公司 &#34;跑赢大盘&#34; 评级。摩根士丹利在周一的研究报告中将 Castle Biosciences 的评级上调至 &#34;买入&#34;。Canaccord Genuity Group 将 Castle Biosciences 的目标价格从 37.00 美元上调至 50.00 美元，并在 12 月 22 日的研究报告中给予公司 &#34;买入&#34; 评级。最后，Weiss Ratings 在 12 月 29 日的研究报告中重申了对 Castle Biosciences 股票的 &#34;卖出 (d)&#34; 评级。八位研究分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股票的共识评级为 &#34;适度买入&#34;，平均目标价格为 47.57 美元。</p>
</div><p><strong>Read Our Latest Research Report on CSTL</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 CSTL 的最新研究报告</strong></p>
</div><h2>About Castle Biosciences</h2>
<div class="lb-trans"><h2>关于 Castle Biosciences</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company's proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.</p>
<div class="lb-trans"><p>Castle Biosciences, Inc 是一家分子诊断公司，专注于为皮肤病患者开发和商业化预后和诊断测试。该公司的专有基因组检测组合旨在改善风险评估并指导皮肤癌及其他皮肤相关疾病患者的临床决策。通过将基因组数据与先进的统计算法相结合，Castle Biosciences 力求提供可操作的见解，帮助医生量身定制治疗方案和监测策略。</p>
</div><p>The company's flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.</p>
<div class="lb-trans"><p>该公司的旗舰测试 DecisionDx-Melanoma 评估皮肤黑色素瘤患者的转移概率，支持更个性化的监测和治疗方法。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Castle Biosciences</li>
<li>The gold chart Wall Street is terrified of…</li>
<li>America’s 1776 happening again</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li>
<li>Unlocked: Elon Musk’s Next Big IPO</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Castle Biosciences</li>
<li>华尔街害怕的黄金图表……</li>
<li>美国的 1776 再次发生</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>用这 4 个简单步骤 &#34;防止美联储&#34; 你的银行账户</li>
<li>解锁：埃隆·马斯克的下一个大 IPO</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1NUTA" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=CSTL"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Castle Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Castle Biosciences 吗？</h2>
</div><p>Before you consider Castle Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Castle Biosciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Castle Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Castle Biosciences 并不在名单上。</p>
</div><p>While Castle Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Castle Biosciences 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Frank Stokes 出售了 7,000 股 Castle Biosciences（NASDAQ:CSTL）的股票